EUVIMEDEUVIMED entdecken
Crossref

Drug‐Associated Nephrotic Syndrome: A Global Pharmacovigilance Perspective

Alexandre Baptista, Ana Macedo, Marreiros, Ana, André Coelho

Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · 20.06.2024

DOI: 10.71749/pkj.42 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT), erschienen am 20.06.2024. Verfasst von Alexandre Baptista und 4 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Nephrotic syndrome is a rare clinical manifestation, with an estimated incidence of 3 cases per 100 000 population per year, which can be triggered by medications contributing to the development of its histopathological forms. The literature references various drugs such as antibiotics, allopurinol, pamidronate, sirolimus, among others. Pharmacovigilance studies enable the evaluation of the safety of these medications in large populations, identifying drugs most strongly associated with the phenotype under investigation.

Methods

This study involved the detection of notifications related to the development of nephrotic syndrome in VigiBase, and assessed the available data based on frequency, disproportionality, and their nephrotoxic role.

Results

During the selected period and among 37 145 123 available notifications, 7211 notifications related to drug‐associated nephrotic syndrome were filtered using the appropriate MedDRA term. These predominantly affected male consumers aged 45‐64 years, with the majority of notifications originating from the USA. Medications classified un‐ der ATC class L‐ antineoplastic and immunomodulating agents, were most frequently involved, and with penicillamine showing the highest association with this phenotype (ROR 231.28), followed by inotersen (ROR 24.49) and sunitinib (ROR 20.31), among others. These notifications had a mortality of 4.2%, with proton pump inhibitors being frequently implicated.

Conclusion

This study assessed VigiBase for the primary medications involved in the development of nephrotic syndrome, both in terms of frequency and associative strength. Clinician involvement is crucial in increasing notifications of adverse drug reactions. Understanding the main agents involved in various renal phenotypes helps improve prescription practices and ensures greater patient safety.

Schlagwörter

nephrotic syndromepharmacovigilanceadverse drug reactionsdrug-induced nephrotoxicityD-penicillamineinotersensunitinibproton pump inhibitorsdisproportionality analysisVigiBase

Zitieren

APA

Baptista, A., Macedo, A., Marreiros, Ana, & Coelho, A. (2024). Drug‐Associated Nephrotic Syndrome: A Global Pharmacovigilance Perspective. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). https://doi.org/10.71749/pkj.42

Vancouver

Baptista A, Macedo A, Marreiros, Ana, Coelho A. Drug‐Associated Nephrotic Syndrome: A Global Pharmacovigilance Perspective. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). 2024. doi:10.71749/pkj.42

BibTeX
@article{Baptista2024,
  author = {Baptista, Alexandre and Macedo, Ana and Marreiros and Ana and Coelho, André},
  title = {Drug‐Associated Nephrotic Syndrome: A Global Pharmacovigilance Perspective},
  journal = {Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)},
  year = {2024},
  doi = {10.71749/pkj.42}
}
Kostenlos starten →